Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
2 "Won Jun Kang"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Gynecologic cancer
Early Assessment of Response to Neoadjuvant Chemotherapy with 18F-FDG-PET/CT in Patients with Advanced-Stage Ovarian Cancer
Young Shin Chung, Hyun-Soo Kim, Jung-Yun Lee, Won Jun Kang, Eun Ji Nam, Sunghoon Kim, Sang Wun Kim, Young Tae Kim
Cancer Res Treat. 2020;52(4):1211-1218.   Published online April 28, 2020
DOI: https://doi.org/10.4143/crt.2019.506
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The aim of this study was to evaluate the ability of sequential 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) after one cycle of neoadjuvant chemotherapy (NAC) to predict chemotherapy response before interval debulking surgery (IDS) in advanced-stage ovarian cancer patients.
Materials and Methods
Forty consecutive patients underwent 18F-FDG-PET/CT at baseline and after one cycle of NAC. Metabolic responses were assessed by quantitative decrease in the maximum standardized uptake value (SUVmax) with PET/CT. Decreases in SUVmax were compared with cancer antigen 125 (CA-125) level before IDS, response rate by Response Evaluation Criteria in Solid Tumors criteria before IDS, residual tumor at IDS, and I chemotherapy response score (CRS) at IDS.
Results
A 40% cut-off for the decrease in SUVmax provided the best performance to predict CRS 3 (compete or near-complete pathologic response), with sensitivity, specificity, and accuracy of 81.8%, 72.4%, and 72.4%, respectively. According to this 40% cut-off, there were 17 (42.5%) metabolic responders (≥ 40%) and 23 (57.5%) metabolic non-responders (< 40%). Metabolic responders had higher rate of CRS 3 (52.9% vs. 8.7%, p=0.003), CA-125 normalization (< 35 U/mL) before IDS (76.5% vs. 39.1%, p=0.019), and no residual tumor at IDS (70.6% vs. 31.8%, p=0.025) compared with metabolic non-responders. There were significant associations with progression-free survival (p=0.021) between metabolic responders and non-responders, but not overall survival (p=0.335).
Conclusion
Early assessment with 18F-FDG-PET/CT after one cycle of NAC can be useful to predic response to chemotherapy before IDS in patients with advanced-stage ovarian cancer.

Citations

Citations to this article as recorded by  
  • The Evaluation Value of CT in the Efficacy of Neoadjuvant Chemotherapy in Ovarian Cancer Patients
    Daying Mou, Shengyan Xie, Pingyuan Li, Mohammad Farukh Hashmi
    Contrast Media & Molecular Imaging.2022;[Epub]     CrossRef
  • Radiomics Analysis of PET and CT Components of 18F-FDG PET/CT Imaging for Prediction of Progression-Free Survival in Advanced High-Grade Serous Ovarian Cancer
    Xihai Wang, Zaiming Lu
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • 8,360 View
  • 135 Download
  • 7 Web of Science
  • 2 Crossref
Close layer
The Relationship between Expression of the Sodium/iodide Symporter Gene and the Status of Hormonal Receptors in Human Breast Cancer Tissue
Hyun Jung Oh, June-Key Chung, Joo Hyun Kang, Won Jun Kang, Dong Young Noh, In Ae Park, Jae Min Jeong, Dong Soo Lee, Myung Chul Lee
Cancer Res Treat. 2005;37(4):247-250.   Published online August 31, 2005
DOI: https://doi.org/10.4143/crt.2005.37.4.247
AbstractAbstract PDFPubReaderePub
Purpose

It has been reported that the sodium/iodide symporter (NIS) gene is expressed in several breast cancer tissues, suggesting the possibility of radionuclide imaging and therapy. However, the regulatory mechanism of NIS gene expression in breast cancer is not yet understood. To assess the relationship between the hormonal status and the NIS expression in breast cancer tissue, we investigated the NIS expression and correlated it to the expression of the thyrotropin receptor (thyroid stimulating hormone receptor, TSH-R), the estrogen receptor (ER) and the progesterone receptor (PR) in human breast cancer tissues.

Materials and Methods

Breast cancer tissues were obtained from 44 patients. Pathological examination showed 2 cases of Grade I, 17 of Grade II, 22 of Grade III, and 3 of unknown grade. We measured the expression of NIS and TSH-R genes by using RT-PCR and we measured the status of ER and PR by using immunohistochemistry.

Results

The NIS gene was expressed in 15 (34%) of the 44 breast cancer tissues. The NIS gene was expressed in 32% of the cases with TSH-R gene expression. The NIS gene was expressed in 40% of the breast cancer tissues with a positive PR and in 31% with a negative PR (p>0.05). It was positive for PR in 18% of the cases and negative for PR in 39% of the cases (p>0.05).

Conclusion

The NIS gene is expressed in approximately one-third of the human breast cancer tissues. Its expression was not related to the presence of the TSH-R gene or hormonal receptors, ER and PR.

Citations

Citations to this article as recorded by  
  • Benign thyroid disease and the risk of breast cancer: An updated systematic review and meta-analysis
    Mingyue Han, Yao Wang, Yuanhui Jin, Xue Zhao, Haiying Cui, Guixia Wang, Xiaokun Gang
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Links between Breast and Thyroid Cancer: Hormones, Genetic Susceptibility and Medical Interventions
    Man Lu, Hanqing Liu, Bilian Zheng, Shengrong Sun, Chuang Chen
    Cancers.2022; 14(20): 5117.     CrossRef
  • Competitive Endogenous Role of the LINC00511/miR-185-3p Axis and miR-301a-3p From Liquid Biopsy as Molecular Markers for Breast Cancer Diagnosis
    Marwa M. Mahmoud, Eman F. Sanad, Reham A.A. Elshimy, Nadia M. Hamdy
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • The correlation between breast cancer and urinary iodine excretion levels
    Fatma Umit Malya, Huseyin Kadioglu, Mustafa Hasbahceci, Kemal Dolay, Mehmet Guzel, Yeliz Emine Ersoy
    Journal of International Medical Research.2018; 46(2): 687.     CrossRef
  • Different expression of sodium–iodide importer (NIS) between lactating breast and thyroid tissues may be due to structural difference of thyroid-stimulating hormone receptor (TSHR)
    X.-Z. Shi, L. Xue, X. Jin, P. Xu, S. Jia, H.-M. Shen
    Journal of Endocrinological Investigation.2017; 40(1): 41.     CrossRef
  • Is there an association between thyroid function abnormalities and breast cancer?
    Anna Angelousi, Evanthia Diamanti-Kandarakis, Evangelia Zapanti, Afroditi Nonni, Eftuxios Ktenas, Aimilia Mantzou, Konstantinos Kontzoglou, Grigorios Kouraklis
    Archives of Endocrinology and Metabolism.2017; 61(1): 54.     CrossRef
  • Iodide transport and breast cancer
    Vikki L Poole, Christopher J McCabe
    Journal of Endocrinology.2015; 227(1): R1.     CrossRef
  • The prognosis and treatment of primary thyroid cancer occurred in breast cancer patients: comparison with ordinary thyroid cancer
    Chang Min Park, Young Don Lee, Eun Mee Oh, Kwan-Il Kim, Heung Kyu Park, Kwang-Pil Ko, Yoo Seung Chung
    Annals of Surgical Treatment and Research.2014; 86(4): 169.     CrossRef
  • Sodium iodide symporter (NIS) in extrathyroidal malignancies: focus on breast and urological cancer
    Salvatore Micali, Stefania Bulotta, Cinzia Puppin, Angelo Territo, Michele Navarra, Giampaolo Bianchi, Giuseppe Damante, Sebastiano Filetti, Diego Russo
    BMC Cancer.2014;[Epub]     CrossRef
  • TSH receptor antibodies have predictive value for breast cancer – retrospective analysis
    Paweł Szychta, Wojciech Szychta, Adam Gesing, Andrzej Lewiński, Małgorzata Karbownik-Lewińska
    Thyroid Research.2013;[Epub]     CrossRef
  • Quantitative Immunohistochemical Analysis Reveals Association between Sodium Iodide Symporter and Estrogen Receptor Expression in Breast Cancer
    Sushmita Chatterjee, Renu Malhotra, Frency Varghese, Amirali B. Bukhari, Asawari Patil, Ashwini Budrukkar, Vani Parmar, Sudeep Gupta, Abhijit De, Pranela Rameshwar
    PLoS ONE.2013; 8(1): e54055.     CrossRef
  • Microarray analysis of genes associated with cell surface NIS protein levels in breast cancer
    Sasha J Beyer, Xiaoli Zhang, Rafael E Jimenez, Mei-Ling T Lee, Andrea L Richardson, Kun Huang, Sissy M Jhiang
    BMC Research Notes.2011;[Epub]     CrossRef
  • Do cell surface trafficking impairments account for variable cell surface sodium iodide symporter levels in breast cancer?
    S. J. Beyer, R. E. Jimenez, C. L. Shapiro, J. Y. Cho, S. M. Jhiang
    Breast Cancer Research and Treatment.2009; 115(1): 205.     CrossRef
  • 11,461 View
  • 64 Download
  • 13 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP